Here we describe the model equations shown schematically in Figure S1 , which is equivalent to the full model schematic as illustrated in Figure 1 . Figure S1 separates out the different strata of the model structure into components, representing separately the baseline epidemic detailing the transmission dynamics of HCV infection ( Figure S1(a) ), the demographic and behavioural aspects of the model, namely stratification by gender, age, injecting drug use ( Figure S1(b) ), medical/community risk ( Figure S1 (c)), and the progression stages of HCV-associated disease ( Figure S1(d) ).
Supplementary Materials 1 Model Structure and Model Equations
Here we describe the model equations shown schematically in Figure S1 , which is equivalent to the full model schematic as illustrated in Figure 1 . Figure S1 separates out the different strata of the model structure into components, representing separately the baseline epidemic detailing the transmission dynamics of HCV infection ( Figure S1 (a)), the demographic and behavioural aspects of the model, namely stratification by gender, age, injecting drug use ( Figure S1 (b)), medical/community risk ( Figure S1 (c)), and the progression stages of HCV-associated disease ( Figure S1(d) ).
The full model is a system of 384 non-linear ordinary differential equations. However, it is foundationally based on the baseline epidemic structure described above, which can be represented by a more basic Susceptible-Infected-Treated (S-I-T) model comprised of three non-linear equations, corresponding to respective compartments of individuals who are susceptible, chronically infected, and undergoing treatment. The full model is then obtained by iteration accordingly to incorporate the aforementioned demographic and behavioural characteristics (gender, age structure, and injecting drug use), epidemic characteristics (disease progression stages from no pathology to cirrhosis, decompensation, and HCC), as well as risk characteristics (low or high medical and community risk factors).
We denote the variables for the general (non-PWID) population in the full model by where the subscripts and superscripts specify the more detailed demographic, epidemic, and risk structures extending from the baseline epidemic model structure as defined in Supplementary  Table S1 . Note that the infected compartments can be written in more compact notation as Note: The subscripts i = 1, 2, 3 for the age structure refer to the Young, Young Adult, and Adult populations, whereas the subscripts j = I, C, D, H refer to the progression states, namely, non-cirrhotic, cirrhotic, decompensated, and HCC, respectively, for the general non-PWID compartments. The corresponding compartments in the Young Adult PWID population are denoted using a different notation as described above, namely, i = PWID and j = Y, U, V, W .
Define each sub-population according to gender and medical/community risk for each age/behaviour category as follows: A detailed description of the model structure and formulation of the model equations is presented below with respect to the different structural characteristics (shown graphically in Figure S1 ), specifically, (i) baseline epidemic structure, (ii) demographic structure, (iii) risk structure, and (iv) disease progression structure. For clarity, we then list the equations explicitly for each age/behaviour class and epidemic/progression stage at the end of this section. These equations are then iterated over the four medical/community risk stages, m, c ∈ {0, 1}, as well as for each gender. Figure S1: HCV model structure components. The model is stratified by infection state including progression, age/behaviour, medical and community risk, and gender.
Baseline Epidemic Structure
The baseline epidemic structure of the model distinguishes individuals that are susceptible to HCV infection, chronically infected, or undergoing treatment, resulting in a SusceptibleInfected-Treated (S − I − T ) model, which is then iterated over the various demographic, risk, and disease progression strata (detailed in the subsequent sections). The equations for the baseline epidemic structure are as follows (refer to Figure S1 (a)):
where the force of infection, λ m,c i,g , is described in detail in Subsection 1.5.
Demographic Structure
To describe the demographic structure, we stratify the population by gender and age/behaviour categories. Specifically, for each gender, we divide the general population into three broad age classes: Young (0-19 years of age), Young Adult Non-PWID (20-29 years of age), and Adult Non-/Ex-PWID (30+ years of age, sometimes simply called Adult), with an additional category to represent the pool of PWID. Because the majority of PWID are young adults and the average duration of injecting is in the order of one decade, we assume that all PWID coincide with the Young Adult age range, which we refer to as Young Adult PWID, or simply as PWID. Each of these age/behaviour compartments can be further stratified into categories according to different levels of medical and community transmission risk, namely, those with both low medical and community risk, high medical risk only, high community risk only, or both high medical and community risk.
With respect to the formulation of the mathematical model, we distinguish gender by the subscript g, where g = g 1 , g 2 refer to male and female gender, respectively. Meanwhile, the three broad age classes are distinguished by the subscript i, where i = 1, 2, 3, refer to the Young, Young Adult Non-PWID, and Adult Non-/Ex-PWID age categories, respectively. The PWID category is considered separately and denoted using different notation.
Newborn individuals enter the model in the Young male or female category according to the birth rate, Λ g , and are assumed to be initially susceptible to HCV infection and not have high medical or community risk. Individuals in the Young category transition to the Young Adult category after an average duration of (1/η 1 ) years, with a small proportion, φ g , initiating injecting drug use at this point (i.e. enter the Young Adult PWID category) and the remainder, (1−φ g ), entering the Young Adult Non-PWID category. Regardless of injecting drug use status, individuals in the Young Adult strata transition to the Adult category after an average duration of (1/η 2 ) years. We assume cessation of injecting drug use (for those in the PWID compartment) upon entering the Adult age category. Individuals in each age category experience age-specific mortality rates (µ 1,g , µ 2,g , and µ 3,g ), with PWID experiencing an additional mortality rate µ due to drug-related factors such as overdose. Because the demographics of Pakistan indicate an increasing population size, the birth rate Λ g is non-constant such that it replaces all natural deaths and also incorporates an additional population growth rate, as detailed below.
The expression for the population birth rate Λ g takes the following form:
where Λ 1,g replaces all natural deaths and Λ 2,g is the growth rate, given below.
the latter of which results in exponential growth of the total population at a constant rate, b g .
Define the population in each age/behaviour group by gender as:
Denote each A i,g for i = 1, 2, PWID, 3 to be the Young, Young Adult Non-PWID (denoted by Young Adult in the equations below), Young Adult PWID, and Adult sub-populations, respectively. Then, these age/behaviour categories satisfy the set of equations (refer to Figure S1 (b)):
Risk Structure
The population is further stratified with respect to low and high medical/community risk categories. Risk structure is distinguished by the superscripts m and c for medical and community risk, respectively, where m, c = 0 correspond to low medical/community risk and m, c = 1 correspond to high medical/community risk. Individuals in a low medical risk stage enter a high medical risk stage at a gender-and age-related rate ν i,g ; meanwhile, those in a low community risk stage enter a high community risk stage at a gender-and age-related rate κ i,g . Thus, at any given time, an individual can be found in one of the following four risk categories: low medical risk & low community risk {m, c} = {0, 0} , low medical risk & high community risk {m, c} = {0, 1} , high medical risk & low community risk {m, c} = {1, 0} , and high medical risk & high community risk {m, c} = {1, 1} . Individuals in any age category can also transition at age and gender specific rates from the low medical and community risk category to either the high medical risk only or high community risk only categories, from which they can then transition to the combined high medical and community risk category (see Figure S1 (c)). We assume that the transition rates of acquiring high medical risk and high community risk are independent and are denoted, respectively, for each age group by ν i,g and κ i,g , where i = 1, 2, 3, or PWID. These states are associated with elevated transmission risk, namely, ψ g and χ g for the respective relative risks of HCV infection associated with high medical risk and high community risk factors, with the transitions to these states being one way because the risk factor data used to parameterise the model only considering ever exposure to risk factors. There is an additional relative risk adjustment factor ρ g when medical and community risks are combined. for each pair of m, c ∈ {0, 1} using the lexicographical ordering mentioned above so that the risk categories are: (Low MR, Low CR) for {m, c} = {0, 0}, (Low MR, High CR) for {m, c} = {0, 1}, (High MR, Low CR) for {m, c} = {1, 0}, and (High MR, High CR) for {m, c} = {1, 1}. Then, the various medical and community risk groups satisfy the set of equations as below (refer to Figure S1 (c)): 
Modelling Disease Progression Due to Long-Term HCV
To estimate the burden of HCV-related morbidity and mortality, we further expand the epidemic structure of the basic age-structured model to incorporate a progression through four health states, namely, chronic infection without disease, cirrhosis, decompensation, and hepatocellular carcinoma (HCC) (see Figure S1 (d)). Each of the health states is stratified using the same S − I − T structure as described in the baseline epidemic structure. We assume that disease progression is uni-directional; that is, there is forward movement, but no backward movement, from an earlier health state into a later one. Moreover, infected individuals who have progressed to a particular disease state (i.e. cirrhotic, decompensated, or HCC) and achieve SVR, either spontaneously or through successful HCV treatment, return to being susceptible, but remain at their present disease state.
Chronic HCV infection leading to the development of cirrhosis occurs at a rate represented in the model by the parameter, σ. Cirrhosis can then progress to decompensation at a rate, γ, and to HCC at a rate, ξ. Resolution of HCV infection at the cirrhotic stage (i.e. SVR) is associated with slower progression either to decompensation or HCC, with a decreased relative risk of CD for the former and CH for the latter. Meanwhile, decompensation can also progress to HCC; however, at this disease state, SVR is not assumed to slow down progression to HCC, i.e. DH = 1. Clinical evidence presented in a systematic review of the natural history of HCV indicates a link between advanced disease progression and increased mortality. 43 To account for this in the model, we assume additional mortality due to decompensation at a rate, µ 4 , and due to HCC at a rate, µ 5 .
For each j ∈ {I, C, D, H}, define the sub-population in each HCV disease progression state as
where J ∈ {I, C, D, H} and K ∈ {Y, U, V, W }.
Denote P j for j ∈ {I, C, D, H} to be individuals with no cirrhosis, compensated cirrhosis, decompensation, and HCC, respectively. Then, disease progression follows the set of equations below (refer to Figure S1 (d)):
where for k ∈ {CD, CH, DH},
1, if infected.
The Force of Infection and Incorporating High Transmission Risk Factors
The force of infection (FOI), λ m,c i,g , describes the rate of HCV transmission and is weighted accordingly to account for factors that can influence this transmission rate, such as age/behaviour as well as differential degrees of medical and community risk exposures. The force of infection specifically associated with HCV transmission due to injecting drug use among PWID is denoted by π i,j Y,g .
We represent the following details in the force of infection:
(i) First, there is a baseline force of infection affecting each age group, which is characterised by an age-specific HCV transmission coefficient β i ;
(ii) Second, PWID are assumed to have an additional force of infection with HCV transmission coefficient θ associated with injecting drug use;
(iii) Third, within each gender, the total and infected populations are weighted by relative risk ratios arising from high medical risk factors (ψ g ) and those associated with high community risk factors (χ g ). There is an additional scaling for the section of the population exposed to combined high medical and community risk factors (ρ g );
(iv) Fourth, mixing between the two genders differs from mixing within each gender in that only high medical risk is assumed to affect the force of infection across both genders, whereas high community risk in one gender is assumed not to influence the force of infection of the opposite gender. In other words, medical risk factors that have an increased relative risk of HCV transmission are shared between genders, but community risk factors are not. This is a plausible assumption based on the results of a multivariate statistical analysis that we have performed on the 2007 national survey data, 46 which suggests that high medical risk factors did not differ by gender, for instance, history of blood transfusions, surgery, or haemodialysis, whereas high community risk factors tended to be genderspecific behaviours such as barbering for males and ear/nose piercings for females (refer to Subsection 3.6 below for further details).
(v) Fifth, we assume that chronically infected individuals who are undergoing treatment do not transmit infection. This assumption is plausible because of the way that DAAs target key points in the HCV life cycle, which can disrupt viral replication and viral assembly. 12 In other words, patients on treatment are assumed to be infected, but not infectious.
Define the various populations weighted by high medical and community risks as follows.
Non-weighted for each gender
Weighted by medical/community risks within each gender
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Weighted by medical/community risks between genders Tot mx wtd,g = R 0,0
The forces of infection at baseline are of the following general form:
Weighted PWID Infectious Weighted Total PWID .
Specifically, for each age/behaviour category, the force of infection at baseline for males and females, respective, is
Tot Inf wtd,g1 + Tot Inf mx wtd,g2 Tot wtd,g1 + Tot mx wtd,g2 , π
Tot PWID wtd,g1 + Tot PWID mx wtd,g2 .
Tot Inf mx wtd,g1 + Tot Inf wtd,g2 Tot mx wtd,g1 + Tot wtd,g2 , π
Tot PWID mx wtd,g1 + Tot PWID wtd,g2 .
Note that we have assumed proportional mixing within each gender according to both medical and community risk factors, whereas assortative mixing with respect to community risk factors only is used to describe the transmission risk between genders (medical risk between genders remains proportional).
It is also assumed that relative risks associated with medical and community factors are independent, and there is an additional relative risk associated with having combined high medical and high community risk.
Lastly, the force of infection in each high-risk category is multiplied by its corresponding relative risk. This represents the additional risk of acquiring infection if susceptible within that particular risk category.
Note that individuals undergoing treatment are still considered infected; however, they are assumed to not be infectious as the anti-viral drugs significantly lower the viral burden within an individual and its potential to transmit between people.
Calculating HCV Infected Incidence
The HCV infected incidence Inc G for a particular subgroup G of all compartments can be calculated from the force of infection, FOI G , using the general formula
We observe that the numerator is a weighted sum of the FOI and the susceptible individuals in each compartment with the weights depending on the FOI for the particular compartment. Meanwhile, the denominator is the total number of susceptible individuals across all compartments of the subgroup of interest.
For instance, to calculate the HCV incidence for non-PWID versus PWID, denote the two subgroups to be G 1 for Non-PWID and G 2 for PWID, respectively. Then,
Model Equations for Epidemic and Disease Progression Stages by Age/Behaviour
In the following, we present the model equations describing the epidemic and disease progression aspects according to age/behaviour. These equations are then iterated over each medical/community risk category for each gender. For each of the four age/behaviour categories, the set of equations shown below is an equivalent representation of the combined epidemic and progression aspects of the full model as shown in Figure 1 (c) in the main text.
Young Population:
Young Adult Non-PWID Population:
Adult Non-/Ex-IDU Population:
HCV Prevalence Trends in Non-PWID Risk Groups in Pakistan
A review was undertaken to collate data on HCV prevalence trends amongst non-PWID populations in Pakistan. Firstly, a review of all available non-PWID data was undertaken and a call to collaborators for HCV prevalence trends (in antenatal women and blood donors) was made. Secondly, collated data was grouped by geographical location and population sub-group. Only those cities and population sub-groups that had 5 or more HCV prevalence estimates were then grouped and graphed to explore whether there was evidence for any trends in HCV prevalence over the years. These trend analyses were then used in the model analyses to parameterise the degree to which the Pakistan HCV epidemic is increasing or decreasing.
Methods

Search Strategy
Our review included a broad literature search of published papers relating to Pakistan HCV studies in order to synthesise available HCV prevalence data within non-high risk populations within Pakistan. Searches were carried out using the Pubmed electronic database. We used a combination of focused computerized retrieval and hand searching, where articles deemed relevant were hand searched for additional publications to identify further references of primary studies that may not have been captured by the computerized search.
Searches were performed using a combination of the following keywords "Pakistan and (hcv or hepatitis c)" and a MeSH term search using the following keywords: ("Hepatitis C" 
Selected Studies
Papers included in the review had to meet the following inclusion criteria: studies conducted in Pakistan or using data from Pakistan studies on the prevalence of hepatitis C in non-high risk populations. Articles that were not accessible through the University Of Bristol institutional library service were requested from the Pakistan research group. 
Results
Characteristics of the Studies
Location of included studies by Pakistan province were as follows: Punjab (n=78), Sindh (n=48), North West Frontier province (n=4), Kyber Pakhtunkhwa (n=21), Balochistan (n=6), Gilgit-Baltistan (n=2), Azad Kashmir (n=1) and studies conducted across Pakistan (n=10).
HCV prevalence data was collected on the following population groups: general population (n=44), paediatric populations (n=9), recruitment for employment (n=23), pregnant women (n=21), blood donors (n=64), patients seeking hospital care (not related to HCV) (n=8), and students (n=1). Studies used a number of different methods to test individuals for HCV antibodies and/or HCV RNA. These included rapid immunochromatographic test (ICT), enzymelinked immunosorbent assay (ELISA), enzyme immunoassays (EIAs), Polymerase chain reaction (PCR), chemiluminescence immunoassay (CIA), gelatin hemagglutination assay (GHA), partcle hemagglutination assay (PHA), recombinant immumoblot assay (RIA) and micro particle immunoabsorbent assay (MEIA).
For documenting prevalence trends over time, sufficient prevalence estimates were only available for blood donors and antenatal women from 5 cities and 1 city, respectively. These included Lahore, Karachi, Peshawar, Islamabad and Rawalpindi for blood donors and Lahore for antenatal women.
The HCV prevalence trends for blood donors in different cities, with associated 95% confidence intervals, are presented in Figures S2(a) -(e). Although the trends in most cities suggest considerable variation, they consistently suggest a stable or slow upward trend over the last 10 to 20 years with greater consistency generally present in the samples with smaller uncertainty (larger sample sizes). When regression lines were fit to these data for each city (shown in each figure), with each prevalence estimate being weighted by its sample size, they all suggest an upward trend over the last 10 or 20 years, although p-values vary. These regression lines suggest that HCV seroprevalence has been increasing by 0.2 to 1.2% every 10 years over this time period. The largest increase was documented in Karachi, which started with one of the lowest HCV seroprevalences at baseline (1% in 1996), and the smallest increase was documented in Lahore and Rawalpindi, which both had a high HCV prevalence at baseline (3-3.5% in 1996).
The HCV seroprevalence trends for antenatal women in Lahore are presented in Figure S2 (f). This data also suggests a fairly stable HCV seroprevalence since 2000 with a possible decline in the last 5 years, which results in our regression line suggesting an overall decline over the whole period. However, it is unlikely that the recent decline is real because the change seems too large (from 8.5 to 5% antibody prevalence over 3 years) for the short time period over which it occurred. For this reason, we have focussed on the blood donor data for determining the likely trends in HCV seroprevalence over the recent past. *The first outlier data point was not included in the regression analysis for Islamabad. 3
The model was parameterised using demographic and HCV prevalence data from a range of sources and calibrated within a probabilistic uncertainty analysis framework to assess the likely uncertainty in our model projections. Estimates for specific model parameters with their uncertainty ranges are shown in Supplementary Table S2 , whereas baseline values and uncertainty ranges for the demographic and epidemiological data used to calibrate the model is shown in Supplementary Table S3 . The average annual growth rate reflects the rapid growth rate of the Pakistan population and is represented by the parameter b g in our age-structured mathematical model. Historical demographic data reported from 1960 suggest that the population was growing faster in the past and slowed down around the year 2000. 49 Moreover, the US Census Bureau projects the average growth rate to fall to 1.33% by the year 2030. 52 To better represent this shift in the demographics of the population, for each gender, we calibrate the parameter b g describing the population growth rate to three different values, one for pre-2000, one for the interim 2000-2015 time period, and one post-2015. To do this, we sample the uncertainty ranges for the total population reported from the demographic data in 1960 and the year 2000. We then calibrate the pre-2000 estimate for the average annual growth rate to the sampled total population in 1960 and 2000. Similarly, the interim 2000-2015 growth rate is calibrated to capture the change in the sampled total population from 2000 to 2015. All total population samples are drawn from their respective uncertainty ranges using a uniform distribution. The post-2015 growth rate is obtained by sampling uniformly from an uncertainty range whose bounds are determined by the minimum and maximum estimated values derived from demographic data for the current growth rate and the projected growth rate up to the year 2030. For each set of demographic data, we back-project the initial population by calibrating it to the sampled total population and growth rates pre-2000. Lastly, we fit the mortality rates accordingly to the proportions in each age category. We assume that there is negligible uncertainty in these proportions representing the age distribution due to the considerable sample sizes.
Population Demographics
Injecting Drug Use
There is a great deal of uncertainty in the proportion of the general population that are PWID. Furthermore, injecting drug use is associated with heightened mortality due to drug-related poisonings; however, no studies to date have explored this issue for Pakistan. We estimate the parameter representing the additional drug-related mortality rate, µ, to be 0.0281 per year for the Asian subcontinent based on a systematic review and meta-analysis from 2013, which calculated the crude mortality rates for PWID by region. 26 Despite making up only a minority of the total population, the subpopulation of young adult PWID exhibits an exceptionally high chronic HCV infected prevalence. 31 To represent the uncertainty in these estimates, we sampled from these ranges assuming a uniform distribution. This then yielded a range of fitted values for the force of infection (i.e. HCV transmission rate) in the subpopulation of young adult PWID.
Chronic HCV Prevalence in the General Population
We calibrate the model to available data on the HCV epidemic in the general Pakistan population. Estimates for HCV seroprevalence are taken from the 2007 national survey on hepatitis B and C involving 47,043 individuals sampled from 7,000 households across Pakistan. 38 The survey classified subjects in five-year age groups and reported HCV seroprevalence in each of these groups, along with an overall HCV sero-prevalence estimate of 4.8% in the general population. 38 
HCV-Associated Disease Progression Including Increased Disease Progression Rates for HCV Genotype 3
Baseline HCV disease progression transition rates were obtained from a meta-analysis and systematic review of fibrosis progression, which estimated annual transition probabilities from F0 to F4 (with respect to the METAVIR scoring system) based on a random effects model. 45 From these stage-specific transition probabilities, we calculated the overall rate from chronic infection without disease to cirrhosis, along with the corresponding uncertainty distributions. Meanwhile, mortality rates were estimated from the results of a UK-based clinical cohort study that estimated transition probabilities pertaining to mortality due to advanced stage liver disease, where the cohort consisted of around 60% men with 50% HCV genotype 1 infection and most of the remainder being genotypes 2 or 3. Supplementary  Table S2 ), which were sampled and then converted to instantaneous rates for parameterisation of the mathematical model.
SVR and Disease Progression
There is evidence that achieving SVR is associated with reduced disease progression from compensated cirrhosis to decompensated cirrhosis or to HCC. 29, 53 However, few studies have looked at the effect of SVR on progression from decompensated cirrhosis to HCC. Two studies evaluating the clinical outcomes of IFN-based HCV treatment 18 and DAA treatment 15 did not find an association between development of HCC and SVR status. Due to a lack of evidence, we assume that there is no benefit of SVR with respect to HCC progression for patients with decompensation.
Medical and Community Risk
In addition to age-stratified data on the HCV epidemic, the 2007 national survey collected detailed information on gender-stratified factors related to medical and community behaviours. We have performed a multivariate statistical analysis on the 2007 national survey data and identified group medical and community factors that were associated with HCV seroprevalence. 46 From the statistical analysis, high medical risk factors included: having greater than five therapeutic injections in the last year, history of blood transfusions, surgery, or haemodialysis. Meanwhile, high community risk factors included: barbering (males only), ear/nose piercings (females), tattoo/acupuncture, and sharing smoking equipment. The results from our statistical analysis show an accumulation of both medical risk and community risk with age amongst males and females, and also suggest that medical risks are shared between genders, whereas community risks are predominantly gender-specific, and we fit our model accordingly to take into account these features.
The model was calibrated to the chronic HCV prevalence within each grouped risk category by gender to estimate the gender-specific relative risk for HCV transmission for each risk category, and to the proportion of individuals within each risk category to estimate age and genderspecific one-way recruitment rates. Specifically, the proportions of individuals within each of Fitting the corresponding model parameters to the risk-stratified HCV infected prevalence data allows us to determine the independent relative risks of acquiring chronic HCV infection associated with high medical and community factors by gender.
Existing and Future Treatment
The public sector has been involved in procuring conventional treatments for HCV using interferon ( Supplementary Table S4 . There is no data on the number of treatments provided by the private sector; however, it is estimated that the provision of HCV treatment from the public sector and private sector is split 40%/60%, based on discussions with the Provincial Hepatitis Control Programs. 36 This split represents a conservative estimate of the total number of historical HCV treatments that were provided nationally between 2005-2015, by considering healthcare system profile and usage data which suggest that, for 1994-2014, one-fifth to one-third of healthcare provision was from the public sector, with no discernable change over time. 32, 34, 35, 41 Thus, we multiply the data for public sector treatment numbers 2.5-fold, yielding the total number of treatments procured between 2005 and 2015 when scaled up across both public and private sectors to be 731,408, with roughly 57,500 total treatments given from 2005 to 2010 and 115,000 up to 150,000 annual treatments thereafter. The HCV treatment rate was calibrated to give these annual historical treatment numbers, with the treatments being assumed to be distributed proportionally to all chronically infected individuals with and without compensated cirrhosis.
Because the dominant HCV genotype in Pakistan is genotype 3, occurring in 80% of HCV infections, we calibrated the model to treatment efficacy for IFN + RBV therapy in such patients. A meta-analysis in 2008 across all relevant studies, not necessarily Pakistan-focussed, reported SVR rates of 68% across HCV genotype 3 patients. 4 The average duration of treatment using these conventional regimens was 24 weeks. Specific to the Pakistani perspective, a review of conventional HCV treatment collated data from numerous in-country studies and found that the reported SVR rates ranged between 50% and 81%. 3, 22, 39, 40, 47 We sample the SVR for conventional treatments uniformly between the lower and upper bound estimates.
From 2016 onwards, the treatment recruitment rate in the model is varied to investigate the range of intervention scenarios under consideration and compared with a treatment rate set to zero for a baseline comparison. Treatment with new direct acting antivirals (DAAs) are welltolerated with a shorter average treatment duration of 12 weeks, and have demonstrated high efficacy in clearing HCV infection, with 90% or over of chronically infected individuals likely to achieve SVR following treatment. 14, 20, 23, 24, 55 However, recent studies on DAA treatment efficacy suggest that HCV genotype 3 is difficult to treat using DAAs, with lower SVR rates from about 80% and above for treatment combinations including sofosbuvir (SOF), RBV, and Peg-IFN. 57 Until late 2017, the only approved DAA in Pakistan was SOF, and so our analyses reflect the challenges associated with treating HCV genotype 3 infections using SOF in the Pakistan context, with reported SVR 12 rates of 84% in a Pakistan-specific treatment cohort. 7
To reflect the uncertainty in the SVR rate for DAA therapy, we sample the model parameter α uniformly between 80% and 95%. We assume that treatment, when specified in the intervention scenarios, is applied to chronically infected individuals with no cirrhosis as well as to cirrhotic individuals, but is not extended to those who have advanced-stage disease, namely, decompensation and HCC.
Model Calibration
To incorporate uncertainty, the parameters and calibration data were sampled 1,000 times from their respective uncertainty distributions as in Supplementary Tables S2 and S3 . For each set of sampled parameters and data, unknown model parameters were varied to fit the model to the calibration data using a non-linear least squares algorithm ('LSQNONLIN'). The parameter sets were then validated by comparing the output of the model for each simulation with the 2007 national survey data, 38 and the increasing HCV prevalence trends from blood donor data (refer to Section 2). A total of 672 model simulations failed to fit within the 95% CI of the HCV prevalence data overall and when stratified by medical and community risk factors and were excluded. The remaining (n = 328) model fits were used for subsequent analyses. The model was solved numerically using an explicit fourth order Runge-Kutta method in Matlab. 9, 42 All model simulations were performed using Matlab Version R2016b, and the linear regression analysis of covariance (ANCOVA) was conducted in Stata Version 14. Figure S5 : Outcome of uncertainty analysis using a linear regression of covariance (ANCOVA) to determine the variability in the 15-year impact on chronic infected prevalence, incidence, and mortality due to the parameter and calibration data for an intervention scenario with a 50% reduction in transmission risk across all groups, and a 5% treatment rate per year. The proportional contribution of each parameter on the model outcome's sum-of-squares was calculated to estimate their importance to the overall uncertainty. 6 Only those parameters and data quantities that contributed greater than 1% of the overall variability in at least one of the three metrics considered are shown.
Supplementary Model Projections and Results
